Benchmark today announced its Q1 Results for the three months ended 31 December 2022.
Highlights include:
- Continuation of consistent year-on-year growth in Revenue and Adjusted EBITDA on a rolling twelve month basis
- Record number of eggs sold in Genetics
- Continued good performance in Advanced Nutrition despite relative softness in the shrimp market
- Significant increase in customer adoption of our sea lice solution, Ectosan® Vet and CleanTreat®
Benchmark has had an excellent start to the year, again showing a continuation of the consistent growth we have seen in revenues and net operating profit on a twelve month rolling basis. This is the result of a good performance in all our business areas. In particular, it is pleasing to see traction in our Health business driven by significantly higher adoption of our sea lice solutions, contributing to a positive financial performance for the quarter.
We are making progress towards our goal of up-listing to the Oslo Børs, the preeminent listing venue for aquaculture and seafood companies globally. This will enable us to increase our visibility with a dedicated group of analysts and investors.
We are grateful to our existing shareholders for their support through the years and we are committed to continuing to deliver improved financial performance and strategic progress for the benefit of all our stakeholders.
